Finasteride for hair loss: mechanism, evidence, side effects, and dutasteride comparison
A complete guide to finasteride for androgenetic alopecia — 5-alpha reductase inhibition mechanism, Merck pivotal trials, sexual side effects and post-finasteride syndrome, dutasteride comparison, and who is a candidate.
· By MedSpot Editorial · 5 min read
Finasteride is the most evidence-backed oral treatment for male androgenetic alopecia (male pattern hair loss) — FDA-approved, supported by decades of controlled trials, and mechanistically precise. It also carries the most discussed side effect profile of any hair loss medication. Here's the complete, unbiased breakdown.
What finasteride is
Finasteride is a synthetic 4-azasteroid — a competitive inhibitor of 5-alpha reductase (5AR) type II, the enzyme responsible for converting testosterone to dihydrotestosterone (DHT) in the scalp, prostate, and liver.
FDA approvals:
- 1 mg: FDA-approved for male androgenetic alopecia (Propecia, 1997)
- 5 mg: FDA-approved for benign prostatic hyperplasia (Proscar, 1992)
Off-label: Finasteride 1–2.5 mg is increasingly used off-label in women with androgenetic alopecia — discussed separately below.
How finasteride works
The DHT-hair follicle connection
In genetically susceptible scalp follicles, DHT (dihydrotestosterone) binds to androgen receptors in dermal papilla cells → triggers follicular miniaturization — a progressive process where each hair cycle produces a thinner, shorter hair, ultimately resulting in terminal-to-vellus hair transition (visible thinning).
DHT is 5× more potent than testosterone at androgen receptors in the scalp. The genetic susceptibility is in the follicular androgen receptor sensitivity, not in DHT levels themselves — which is why men with AGA often have normal serum DHT.
Finasteride's mechanism
Finasteride competitively inhibits 5AR type II:
- Reduces scalp DHT by ~60–70%
- Reduces serum DHT by ~65%
- Testosterone levels increase modestly (by ~15%) as conversion to DHT is blocked
By reducing DHT, finasteride slows or halts follicular miniaturization — and in many patients allows partial reversal (miniaturized follicles produce thicker hair again).
Clinical evidence
Merck pivotal trials (1–2 mg/day, men)
Finasteride's approval rests on two large multicenter RCTs:
Kaufman et al. (1998, Journal of the American Academy of Dermatology) — 1,553 men aged 18–41 with mild-to-moderate AGA, randomized to finasteride 1 mg vs. placebo for 2 years:
- 83% of finasteride group maintained or increased hair count vs. baseline
- 48% of placebo group continued to lose hair
- Mean hair count increased +107 hairs/cm² (vertex) in finasteride group vs. -75 hairs/cm² in placebo
- Global photographic assessment: 80% rated as improved by blinded investigators
Long-term (5 years, Kaufman et al. 1999): Efficacy maintained at 5 years with continued use; discontinuation results in return to pre-treatment hair loss trajectory within 6–12 months.
Scalp hair vs. frontal hairline
Finasteride is more effective for vertex (crown) hair loss than frontal hairline recession. The reasons are not fully characterized but likely relate to androgen receptor density differences between scalp regions. For advanced frontal recession, finasteride slows loss but produces less visible regrowth.
Side effects: the complete picture
Sexual side effects
The most discussed concern — documented in clinical trials and subsequent population studies:
Trial-reported rates (finasteride 1 mg):
- Decreased libido: ~1.8% (vs. 1.3% placebo)
- Erectile dysfunction: ~1.3% (vs. 0.7% placebo)
- Ejaculation disorder: ~1.2% (vs. 0.7% placebo)
In the clinical trials, these resolved on discontinuation in the majority of affected patients.
Post-finasteride syndrome (PFS)
A subset of patients report persistent sexual and cognitive side effects after discontinuing finasteride — including persistent erectile dysfunction, reduced libido, decreased penile sensitivity, brain fog, depression, and anxiety — that do not resolve with cessation.
The evidence status: PFS is contested in the medical literature:
- The Post-Finasteride Syndrome Foundation and patient advocacy groups have documented thousands of cases
- The FDA updated finasteride's label in 2012 to include persistent sexual dysfunction after discontinuation
- The biological mechanism is hypothesized to involve neurosteroid synthesis disruption (5AR converts progesterone to neurosteroids in the brain) but remains unproven
- Epidemiological studies disagree on incidence — estimates range from <1% to several percent of users
Honest clinical position: PFS is a real reported phenomenon in a subset of patients. The incidence is unknown but likely below 5%. It cannot be predicted in advance. Patients should be fully informed before starting finasteride.
Other side effects
- Breast tenderness/gynecomastia: ~0.5%; higher with 5 mg doses
- Elevated PSA suppression: Finasteride reduces PSA by ~50% — inform any urologist monitoring PSA
- Teratogenicity: Finasteride is absolutely contraindicated in pregnancy and for women who may become pregnant (crushed tablets are absorbed through skin). Women should not handle crushed or broken finasteride tablets.
- Mood changes: Depression and anxiety — less established than sexual effects; under investigation
Finasteride vs. dutasteride
Dutasteride inhibits both 5AR type I and type II (vs. finasteride's type II only):
| Finasteride 1 mg | Dutasteride 0.5 mg | |
|---|---|---|
| 5AR inhibition | Type II only | Type I + II |
| Scalp DHT reduction | ~60–70% | ~90% |
| Serum DHT reduction | ~65% | ~90–95% |
| FDA approval for AGA | Yes (1 mg) | No (off-label for AGA) |
| FDA approval for BPH | Yes (5 mg) | Yes (0.5 mg) |
| Hair regrowth evidence | Very strong | Strong (slightly superior) |
| Side effect profile | Established | Similar; potentially higher at BPH doses |
| Half-life | 5–6 hours | ~5 weeks |
Clinical implication: Dutasteride produces greater DHT suppression and in head-to-head trials produces modestly greater hair regrowth than finasteride. However, its extremely long half-life (5 weeks) means side effects — if they occur — take much longer to resolve after discontinuation. The FDA has not approved dutasteride for AGA (though Korea has, and it is standard practice in Korean dermatology).
Finasteride in women
Finasteride is used off-label for female androgenetic alopecia at doses of 1–2.5 mg/day. Evidence base is smaller than the male AGA data:
Iorizzo et al. (2006) — a controlled study of finasteride 2.5 mg/day in postmenopausal women with AGA found significant improvement in hair density vs. placebo.
Premenopausal women: Must use reliable contraception — finasteride is absolutely contraindicated in pregnancy. Many prescribers require OCP co-prescription. The risk-benefit calculation is individualized.
Combination therapy
The strongest medical protocol for male AGA combines finasteride + minoxidil (topical or low-dose oral):
Khandpur et al. (2020, JAMA Dermatology)** — RCT of finasteride vs. minoxidil vs. combination found the combination produced significantly greater hair density improvement than either monotherapy.
Mechanism rationale: Finasteride reduces the hormonal driver (DHT); minoxidil directly stimulates the follicle through KATP channels and VEGF — completely different pathways. Combination is additive.
Accessing finasteride
- In-person: Dermatologist or primary care physician
- Telehealth: Hims, Roman, Keeps, Apostrophe — commonly prescribe finasteride for AGA; some offer minoxidil combination packages
- Cost: Generic finasteride 1 mg is inexpensive ($10–$30/month at pharmacy)
Looking for a hair loss consultation? Browse hair restoration providers on MedSpot →